Oral premalignant lesions: Any progress with systemic therapies?

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 205-210

  William, William N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

chemoprevention; leukoplakia; oral premalignant lesions

Indexed keywords

CELECOXIB; CETUXIMAB; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GREEN TEA EXTRACT; ISOTRETINOIN; KETOROLAC; MOLECULAR MARKER; PIOGLITAZONE; PODOPLANIN; PROTEIN P53; PROTEIN P63; TROGLITAZONE;

ALLELIC IMBALANCE; CANCER PREVENTION; CANCER RISK; CARDIOTOXICITY; CHEMOPROPHYLAXIS; DNA METHYLATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GENE DOSAGE; GENE EXPRESSION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; LEUKOPLAKIA; MALIGNANT TRANSFORMATION; MOUTH CANCER; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; SYSTEMIC THERAPY;

EID: 84859823043     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835091bd     Document Type: Review

References (59)

1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35:1332-1338.
2. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8:314-346.
3. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer: a plan to move forward. Clin Cancer Res 2006; 12:3661-3697. (Pubitemid 44000248)
4. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001; 344:1323-1326. (Pubitemid 32372968)
5. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6:357-362. (Pubitemid 30111451)
6. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009; 8:213-225.
7. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980; 8:283-333.
8. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 2003; 39:770-780. (Pubitemid 38373461)
9. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53:563-568. (Pubitemid 14182737)
10. William WN Jr, Liu C, Lippman SM. Chemoprevention of head and neck cancers. In: Olshan AF, editor. Epidemiology, pathogenesis and prevention of head and neck cancers. 1 ed. New York, New York: Springer; 2010. pp. 107-202.
11. van der Waal I, Axell T. Oral leukoplakia: a proposal for uniform reporting. Oral Oncol 2002; 38:521-526. (Pubitemid 34880114)
12. Pindborg JJ, Daftary DK, Mehta FS. A follow-up study of sixty-one oral dysplastic precancerous lesions in Indian villagers. Oral Surg Oral Med Oral Pathol 1977; 43:383-390. (Pubitemid 8058336)
13. Pindborg JJ, Reibel J, Holmstrup P. Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol 1985; 14:698-708.
14. Abbey LM, Kaugars GE, Gunsolley JC, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80:188-191.
15. Karabulut A, Reibel J, Therkildsen MH, et al. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995; 24:198-200.
16. Cruz IB, Snijders PJ, Meijer CJ, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998; 184:360-368.
17. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488-2492. (Pubitemid 26170679)
18. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682-685. (Pubitemid 26191956)
19. Partridge M, Emilion G, Pateromichelakis S, et al. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 1998; 34:77-83. (Pubitemid 28207005)
20. Partridge M, Pateromichelakis S, Phillips E, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000; 60:3893-3898. (Pubitemid 32204583)
21. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 2002; 62:6447-6450. (Pubitemid 35364104)
22. Sardi I, Franchi A, Ferriero G, et al. Prediction of recurrence by microsatellite analysis in head and neck cancer. Genes Chromosomes Cancer 2000; 29:201-206.
23. Abbruzzese JL, Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 2004; 6:321-326. (Pubitemid 39361433)
24. Bhutani M, Pathak AK, Fan YH, et al. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) 2008; 1:39-44.
25. Boyle JO, Gumus ZH, Kacker A, et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) 2010; 3:266-278.
26. Sridhar S, Schembri F, Zeskind J, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008; 9:259.
27. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501-1505. (Pubitemid 17052146)
28. Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988; 40:93-101.
29. Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42:195-199.
30. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997; 33:231-236.
31. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328:15-20. (Pubitemid 23011466)
32. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997; 89:257-258. (Pubitemid 27073764)
33. Papadimitrakopoulou VA, Lee JJ, William WN Jr, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without betacarotene in oral premalignancy. J Clin Oncol 2009; 27:599-604.
34. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90:1545-1551. (Pubitemid 28535719)
35. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702-1710. (Pubitemid 30305062)
36. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26:354-360. (Pubitemid 351171684)
37. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, et al. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res 2009; 15:6284-6291.
38. Taoudi Benchekroun M, Saintigny P, Thomas SM, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 2010; 3:800-809.
39. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001; 7:3127-3134. (Pubitemid 32963834)
40. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003; 95:198-205. (Pubitemid 36240632)
41. Saintigny P, Zhang L, Fan YH, et al. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 2011; 4:218-229.
42. Saintigny P, Jelinek J, Pickering CR, et al. DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. J Clin Oncol 2011; 29:1506.
43. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
44. Leeman-Neill RJ, Seethala RR, Singh SV, et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) 2011; 4:230-237.
45. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24:792-799. (Pubitemid 34857307)
46. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10:1565-1573. (Pubitemid 38435544)
47. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008; 14:2095-2101. (Pubitemid 351551121)
48. Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 2010; 3:900-909.
49. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med 1999; 220:218-224.
50. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009; 2:931-941.
51. Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009; 69:1712-1716.
52. Zhang X, Zhang H, Tighiouart M, et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008; 123:1005-1014.
53. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25:1476-1481. (Pubitemid 46733074)
54. Govindarajan R, Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: 1511.
55. Suzuki R, Kohno H, Suzui M, et al. An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis 2006; 27:619-630. (Pubitemid 43372890)
56. Yoshida K, Hirose Y, Tanaka T, et al. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003; 94:365-371. (Pubitemid 36626370)
57. Rhodus N, Rohrer M, Pambuccian S, et al. Phase IIa chemoprevention clinical trial of pioglitazone for oral leukoplakia. J Dent Res 2011; 90(A): 945.
58. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21:4546-4552. (Pubitemid 46594025)
59. Li Y, Li LJ, Zhang ST, et al. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 2009; 15:6724-6731.